DMXE

Argentina controls DMXE through the arylcyclohexylamine chemical-group schedule in Annex II of Decree 560/2019 rather than by individual name. Its PCE-derived ethylamino group, meta-methyl aromatic substitution, and 2-oxo cyclohexanone core match the relevant Group 2 structure and its permitted amino-alkyl and aromatic-alkyl substitutions. Article 2 treats substances within the Annex II chemical groups as estupefacientes for article 77 of the Penal Code; Decree 122/2026 replaces only Annex I and leaves this group schedule in place.

At Commonwealth level, DMXE is covered as a controlled-drug and border-controlled-drug analogue of listed ketamine. The US FDA substance registry identifies DMXE as deoxymethoxetamine and 2-(ethylamino)-2-(3-methylphenyl)cyclohexan-1-one, while the UK Advisory Council on the Misuse of Drugs identifies deoxymethoxetamine among ketamine analogues; section 301.9 covers specified group and atom replacements and other analogues or chemical derivatives. The Criminal Code Regulations 2019 list ketamine in Schedule 1 item 146 and Schedule 2 item 110, so sections 301.1 and 301.4 extend federal controlled-drug and border-controlled-drug status to the analogue.

Austria's NPS regulation covers every compound derivable from the arylcyclohexylamine core structure, which encompasses DMXE. The NPS Act penalizes profit-motivated manufacture, import, export, transfer, or procurement carried out with the intent that the substance be used for psychoactive effect.

Belgium's current regulator-published consolidated Annex IV expressly lists deoxymethoxetamine (DMXE). The listing places DMXE among the substances nationally controlled under the royal decree on narcotic drugs and psychotropic substances.

Canada defines an analogue as a substance with a substantially similar chemical structure to a controlled substance. Schedule I covers phencyclidine and its derivatives and analogues, expressly including ketamine; DMXE is an arylcyclohexanone in this analogue family, although application of the substantial-similarity definition remains a chemical and legal classification question.

The Shenzhen Public Security Bureau's official controlled-drug catalogue, published 17 July 2026 and expressly current through 1 July 2026, lists entry 199 as 2-乙氨基-2-(3-甲基苯基)环己酮 / 2-(Ethylamino)-2-(3-methylphenyl)cyclohexan-1-one, CAS 2666932-45-0, abbreviation DMXE. The three-agency 2025 consolidation announcement states that the Catalogue of Non-medical Narcotic Drugs and Psychotropic Substances took effect upon publication and simultaneously repealed the former Supplementary Catalogue. A further three-agency announcement added 16 substances effective 1 July 2026; the later official police consolidation retains DMXE as entry 199. Regulation Articles 3 and 4 establish the three-agency non-medical catalogue and permit a listed non-medical substance to be used only for experimental research conducted under the Regulation, while prohibiting production, operation, use, storage, and transport. Public Security Administration Punishments Law Article 84 penalizes illegal possession of a small quantity of other drugs. Criminal Law Article 348 penalizes illegal possession of larger quantities of other drugs, and Article 357 defines drugs to include other state-controlled addictive narcotic drugs and psychotropic substances. DMXE is therefore prohibited for ordinary possession and use, subject to the Regulation's narrow experimental-research authorization.

Colombia's sanitary code treats Ministry-designated psychopharmaceuticals, their precursors, and any other substance of analogous nature as restricted. The current national schedule names methoxetamine (MXE), 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone, while the UK Advisory Council on the Misuse of Drugs identifies DMXE as an MXE analogue with the chemical name 2-(ethylamino)-2-(3-methylphenyl)cyclohexan-1-one. DMXE therefore falls within the statutory analogue restriction; Annex 4 separately covers salts and stereoisomers of substances in Green List II.

The current Annex 1 expressly lists DMXE in List I as deoxymethoxetamine and identifies it as 2-(ethylamino)-2-(3-methylphenyl)cyclohexanone and 2-(ethylamino)-2-(m-tolyl)cyclohexanone. Regulation No. 33 of 6 August 2026 replaced Annex 1 in full and took effect on 14 August 2026. Under §§ 2(1) and 3(1) of the Narcotic Drugs and Psychotropic Substances and Precursors Act, substances in the ministerial lists are narcotic or psychotropic substances and their handling is prohibited except for the Act's medical, scientific, law-enforcement, and statutory teaching purposes. The official revision history identifies consolidated text 111082026010 as the latest version; RT I, 11.08.2026, 9 is the publication reference for the amending regulation, not RT I, 11.08.2026, 10.

Germany controls DMXE through the arylcyclohexyl(methyl)amine substance group in Anlage 1 no. 6 of the NpSG rather than by individual name. DMXE's N-ethyl group, methyl-substituted phenyl ring, and cyclohexanone oxo group fit the provision's permitted alkyl R1/R2, alkyl-substituted phenyl R3, and oxo Rn parameters within the 500 u mass ceiling. Sections 2 and 3 classify substances in an Anlage 1 group as new psychoactive substances and prohibit trade, placing on the market, manufacture, import, export, transit, acquisition, possession, and administration, subject to statutory exceptions.

Ireland's capacity-based definition covers a substance that depresses the central nervous system and produces significant changes in perception, awareness, mood, or related functions. The Act criminalizes knowing or reckless sale, import, or export for human consumption; it does not create a general personal-possession offence.

Israel's First Schedule lists deschloroketamine (DCK) and expressly includes structural derivatives of that substance. DMXE, 2-(ethylamino)-2-(3-methylphenyl)cyclohexan-1-one, differs from the listed DCK structure through substitution of the amino alkyl group and addition of a methyl group to the phenyl ring; both changes fall within the schedule's definition of a structural derivative. DMXE is therefore covered as a dangerous-drug analogue rather than named separately.

DMXE is listed in Italy as deossimetossietamina in Table I of D.P.R. 309/1990. The Central Directorate for Anti-Drug Services' 2024 report records its 2021 inclusion in Table I and identifies a 2023 police notification, so it is treated as a prohibited Table I substance.

Japan designated DMXE under the Pharmaceuticals and Medical Devices Act by Ministry ordinance, effective 8 July 2022. Manufacture, import, sale, possession, and use of the substance and products containing it are generally prohibited except for authorized purposes.

DMXE is treated as a Class C controlled-drug analogue under section 2(1) of the Misuse of Drugs Act 1975. New Zealand's Ministry of Health defines drug analogues by substantial structural similarity to a controlled drug and describes their automatic capture as Class C; the UK Advisory Council on the Misuse of Drugs identifies deoxymethoxetamine among ketamine analogues, while New Zealand's Medsafe identifies ketamine as a C4 controlled drug.

Poland lists DMXE under the name 3D-MXE (deoksymetoksetamina) as item 55 in Annex 3's list of new psychoactive substances. The item remains in the consolidated 2024 regulation as amended in 2025 and 2026; neither amendment repeals or replaces item 55. Article 62b of the Act on Counteracting Drug Addiction penalizes possession of new psychoactive substances, with increased penalties for a significant quantity.

Russia controls DMXE through the List I entry for 1-phenylcyclohexylamine and its derivatives under Government Decree No. 681. DMXE's official chemical identity, 2-(ethylamino)-2-(3-methylphenyl)cyclohexanone, differs from 1-phenylcyclohexylamine by formal hydrogen substitutions with ethyl and methyl groups and by replacement of two ring hydrogens with divalent oxygen; the carbon-bearing substituents add three carbons, within note 6's carbon-count ceiling. List I covers narcotic drugs, psychotropic substances, and precursors whose circulation is prohibited in Russia.

DMXE is not individually named in Singapore's current First Schedule, but the Misuse of Drugs Act 1973 covers an unlisted substance as a psychoactive substance when it has the capacity to stimulate or depress the central nervous system and affect mental functioning or emotional state, unless it is excluded under the Fifth Schedule. A 2026 UK government review identifies deoxymethoxetamine as a ketamine analogue detected in drug seizures, and Singapore's Central Narcotics Bureau states that unlisted NPS with psychoactive capacity are dealt with as psychoactive substances. Sections 11F to 11I make unauthorised trafficking, manufacture, import, export, possession and consumption offences, subject to the Act's legitimate-purpose defences.

DMXE is covered as an undesirable dependence-producing substance through Part III of Schedule 2 rather than by an individual name. Part III lists phencyclidine and its congener PCE, then extends coverage to chemically related homologues incorporating a similar structural fragment or exhibiting similar pharmacodynamic properties; Japan's Ministry of Health identifies DMXE as 2-(ethylamino)-2-(3-methylphenyl)cyclohexanone and 3′-methyl-2-oxo-PCE, while the UK Home Office classifies it as an arylcyclohexylamine covered by a generic phenylcyclohexylamine clause. Sections 4 and 5 prohibit unauthorized possession, use, and dealing, subject to the Act's medicinal and permit exceptions.

South Korea's Narcotics Control Act Enforcement Decree treats compounds within the structure-based phencyclidine-analogue definition in Annex 3, item 21 as category (a) psychotropic substances. DMXE's 2-(ethylamino)-2-(3-methylphenyl)cyclohexanone structure matches the provision's N-alkylamino group, substituted phenyl ring, and oxygen options, so it is covered even though DMXE is not individually named.

Sweden's narcotics-control ordinance expressly lists deoxymethoxetamine (DMXE), identified as 2-(ethylamino)-2-(3-methylphenyl)cyclohexan-1-one. The amendment entered into force on 11 July 2023 and classifies DMXE as a narcotic drug.

DMXE is expressly listed as Deoxymethoxetamin, with the matching chemical name 2-Ethylamino-2-(3-methylphenyl)cyclohexan-1-on, at number 287 of Annex 6, list e, in the current BetmVV-EDI consolidation dated 13 March 2026. BetmVV-EDI Articles 1 and 2 make Annex 6/list e substances controlled substances. BetmG Article 7 requires EDI authorisation to cultivate, manufacture, import, export, store, use, or market them, and Article 20(1)(c) penalises those activities without authorisation. AS 2021 815 added number 287 and brought the amendment into force on 6 December 2021 at 10:00; the current schedule retains DMXE without a substance-specific exemption.

Presidential Decision No. 4501 expressly lists deoxymethoxetamine as 2-(ethylamino)-2-(3-methylphenyl)cyclohexanone. Its operative clause subjects every substance in the annex to Law No. 2313 on the Supervision of Narcotic Drugs. DMXE is therefore prohibited in Turkey as a named controlled substance rather than through analogue or blanket-class coverage.

DMXE is controlled as a Class B drug through the Misuse of Drugs Act's generic arylcyclohexylamine wording. The Home Office has identified deoxymethoxetamine as Class B, and the Advisory Council states that the generic provision controls methoxetamine-related compounds as Class B and Schedule 1 substances.

DMXE is expressly listed as Deoxymethoxetamin in the current annex to Government Regulation No. 11/2025 Coll., with the chemical name 2-(ethylamino)-2-(3-methylfenyl)-cyklohexanon. Section 33j of Act No. 167/1998 Coll. treats manufacture, export, import, distribution, market-directed acquisition and placing on the market as handling, and prohibits that handling except for research. The regulation also covers stereoisomers, salts and esters of listed substances where they can exist.

DMXE is listed by the synonym 3-Me-2-oxo-PCE and the name Deoxymethoxetamin as item 302 of Denmark's List B. List B substances may be used only for medical or scientific purposes, and handling requires authorization from the Danish Medicines Agency; import and export additionally require a certificate for each case. The substance has been under this control since 12 February 2023.

DMXE is directly listed under its Finnish name, deoksimetoksetamiini, in the current appendix to Government Decree 1130/2014 on psychoactive substances prohibited from the consumer market. Under section 5 of the Narcotics Act 373/2008, manufacture, import into Finland, storage, offering for sale, and transfer of substances in this category are prohibited, subject to the statutory research and industrial-use exceptions.